Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9368690 | 0.88 | ALDH1A1 (0.44) | ALDH1A1KMT2AKDM4EPOLBGAA | |
| SCHEMBL505209 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KMT2AKDM4EPOLBLMNA | |
| SCHEMBL29745000 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KMT2AKDM4EPOLBLMNA | |
| SCHEMBL9368692 | 0.81 | GPR35 (0.53) | ALDH1A1KMT2AKDM4EGAAMEN1 | |
| SCHEMBL4778269 | 0.79 | POLB (0.65) | ALDH1A1KMT2AKDM4EPOLBLMNA | |
| SCHEMBL27696403 | 0.79 | AR (0.58) | — | |
| SCHEMBL16830984 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KMT2AKDM4EPOLBLMNA | |
| Hydrochloric Acid SCHEMBL6559022 | 0.78 | POLB (0.63) | ALDH1A1KMT2AKDM4EPOLBLMNA | |
| SCHEMBL8656426 | 0.75 | ALDH1A1 (0.50) | ALDH1A1KMT2APOLBLMNAGAA | |
| SCHEMBL16486509 | 0.75 | KAT2B (0.49) | ALDH1A1KMT2APOLBLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105829305-B | NRF2 regulator | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-11-30 | — | — | CN | disclosed |
| EP-1549344-A1 | PHARMACEUTICAL COMPOSITIONS DIRECTED TO ERB-B1 RECEPTORS | MERCK PATENT GmbH (DE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1549345-A1 | BISPECIFIC ANTI-ERB-B ANTIBODIES AND THEIR USE IN TUMOR THERAPY | MERCK PATENT GmbH (DE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004032961-A1 | BISPECIFIC ANTI-ERB-B ANTIBODIES AND THEIR USE IN TUMOR THERAPY | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004032960-A1 | PHARMACEUTICAL COMPOSITIONS DIRECTED TO ERB-B1 RECEPTORS | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |
| EP-1385546-A1 | COMBINATION THERAPY USING ANTI-EGFR ANTIBODIES AND ANTI-HORMONAL AGENTS | MERCK PATENT GmbH (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002089842-A1 | COMBINATION THERAPY USING ANTI-EGFR ANTIBODIES AND ANTI-HORMONAL AGENTS | MERCK PATENT GMBH (DE) | 2002-11-14 | — | — | WO | disclosed |